Late-Breaking Research: Immunology 3

• LB252 · PDF ABN202, a TROP2-targeted IFN-beta mutein fusion protein, overcomes ADC resistance and elicits durable CD8⁺ T cell-dependent antitumor immunity Hee Geon Park, Myeung Ryun Seo, Hyun Kyung Lee, Sang Moo Lee, Su Jin Ryu, Ho Jin Lee, Rae Eon Kim, Sung Hyun Hong, Su Jin Lee, Sang In Lee, Seung Hwa Jeong, Jae Mun Kim, Sung Youl Hong, Jangsoon Lee, Naoto T. Ueno, Yeon Hee Park, Young Kee Shin
• LB253 · PDF Discovery of A-911, a potent, orally bioavailable 5-HT7 antagonist that promotes DC1-mediated T-cell cross-priming and anti-tumor immunity Kenneth D. Bromberg, Jacob Gorman, Jun Guo, Douglas E. Kline, Daniel T. Cohen, Paul Ellis, David Peetz, Luis Rodriguez, Sven Malchow, Cara Hrusch, Ryan Duggan, Min Cheng, Todd Hopkins, Bailin Shaw, Val Manaves, Danli Towne, Sujatha Gopalakrishnan
• LB254 · PDF Redirecting cytomegalovirus immunity against breast tumors for immunotherapy Catarina Maia, Philip Salu, Rithika Medari, Remi Marrocco, Eduardo Lucero Meza, Kwangsun Yoo, Andrew Lowy, Christopher Benedict, Tatiana Hurtado de Mendoza
• LB257 · PDF MST-0312: Targeted LTBR agonist designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) for the treatment of solid tumors Marta Lewandowska, Ann White, Lucy Penfold, Fevzi Demircioglu, Charly Brown, Robert de Jonge, Ray Jupp, Pascal Merchiers
• LB258 Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T cell exhaustion and reinvigorates antitumor immunity Zhenhua Ren, Xiaohng Yu, Yang-Xin Fu
• LB259 · PDF A novel tumor-microenvironment-responsive pro-TCE therapy minimizes cytokine release for safer solid tumor treatment Yang Wang, Wei Huang, Lixia Cao, Cui Feng, Lixia Gu, Fangdun Jiang, Yifan Yang, Qi Zhang, Chen Li, Ming Zhou, Cancan Li, Bonan Yan, Ziping Wei, Yuhong Zhou
• LB260 · PDF A novel anti-PD-1×CTLA-4×VEGF tri-specific antibody enables tumor-selective immune checkpoint blockade with potent anti-tumor activity Xiaochuan Ma, Jie Zhao, Gang Deng, Guoyong Bian, Xinping Huang, Shu Wang, Zhibin Xu, Zhendong Xue, Limin Zhang, Chunyue Wang, Hanxiao Ying, Emily Wu, Jun Feng, Min Hu, Feng He
• LB261 · PDF ProTCE-PSMA, a novel therapeutic PSMA/CD3 prodrug for prostate cancer Pu Pu, Le Huang, Xiaoning Li, Ting Zhang, Huaixin Dang, Xiaoying Yang, Qiuchen Zheng, Weiyun Wen, Zhendong Xue, Yuchang Mao, Limin Zhang, Chunyue Wang, Hanxiao Ying, Emily Wu, Jun Feng, Min Hu, Feng He
• LB263 · PDF BCG047, a novel heavy chain antibody-drug conjugate targeting FOLR1, demonstrates outstanding preclinical antitumor efficacy Benny Yang, Yifu Zhang, Yangyang Xu, Chengzhang Shang
• LB264 · PDF Turning cold tumors hot: Targeted TNF potentiates the activity of bispecific T cell engagers in solid tumors Gudrun Thorhallsdottir, Ramon Benz, Pinuccia Faviana, Francesco Bartoli, Samuele Cazzamalli, Emanuele Puca, Dario Neri, Abdullah Elsayed
• LB265 · PDF AGB101, a first-in-class Vbeta17 x DLL3 bispecific antibody, selectively redirects Vbeta17 T memory cells to drive robust DLL3 dependent anti-tumor activity Natasa Obermajer, Jessie Richardson, Daniel Masylar, Karin Thacker, Matthew V. Lorenzi, Iqbal S. Grewal
• LB266 · PDF VBC229: A novel DLL3-targeting biparatopic T-cell engager-topoisomerase I inhibitor fusion molecule for depth and duration of response in small-cell lung cancer Wei (Vivian) Wang, Xuekun Zhang, Kevin Yin, Man Xu, Jim Li, Jian Tang, Xingguang Lin, Yingchun Wang, Yanwei Wang, Xin Li, Delong Zhang, Jing Li
• LB267 · PDF CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors James Legg, Mark Uden, Robert Good, Julie Hoong, Alex Laskowska, Fevzi Demircioglu, Roseanna Hare, Shauna Corcoran, Valentina Cazzetta, Joanna Mikulak, Luke Cave, Carlotta Cattolico, Leia Griffin, Domenico Mavilio, Natalie Mount
• LB268 · PDF Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers Mingming Gao, Susan Liuchen, Jufang Lin, Bingshuang Xu, Yan Ding, Qiaoxin Zeng, Zhixiong Zhang, Li Cao, Chunzhe Guo, Tao Liu, Ning Jiao, Yong Peng, Shaojing Hu
• LB269 · PDF Mechanistic insights into the pharmacology of CDR609 support high potential as a targeted immunotherapy Athanasia Dasargyri, Alessio Vantellini, André Fonseca, Anna Howald, Blaz Pavlovic, Alice Langer, Martina Priola, Nora Wettstein, Zoi Barou, Cedric Kiss, Hannes Merten, Sophie Barsin, Stephanie Jungmichel, Leonardo Borras
• LB270 · PDF TCE-A: An “OR-gate” CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune diseases Hanxiao Ying, Emily Wu, Sizhu Duan, Dongmei Bai, Jing Wang, Pu Pu, Limin Zhang, Chunyue Wang, Min Hu, Feng He
• LB272 · PDF A neoantigen mRNA vaccine generates antitumor immunity in a murine model of intrahepatic cholangiocarcinoma Mantang Qiu, Jiacheng Lu, Xinghan Wu, Yang Liu, Guoming Shi

在完整检索应用中浏览本分会场 →